Company intelligence / Profile preview

HWEL Holdings

Paramus, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Starton is transforming standard-of-care therapies—especially in hematologic cancers—by developing proprietary continuous delivery technologies that may improve drug efficacy, tolerability, and patient quality of life. Its technology is designed to minimize side effects of existing drugs (e.g., lenalidomide) and expand their use by enabling more tolerable, continuous administration via subcutaneous or transdermal systems. The company expects its first clinical milestones in 2023.

Therapeutic areas: Oncology
Modalities: Small moleculeDrug delivery device
Industry: Biotech

Partnerships

Healthwell Acquisition Corp. I

Beyond the preview

Go deeper on HWEL Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HWEL Holdings.

Explore the full profile